ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Ankylosing spondylitis (AS)"

  • Abstract Number: 0421 • ACR Convergence 2024

    The Effect of Biologic Treatment for Psoriatic Arthritis and Axial Spondyloarthritis on Semen Parameters – a Longitudinal Study

    Katya Meridor1, Shimi Barda2, sara Pel3, sharon Nevo2, Julia Berman2, daphna paran4, Ori Elkayam5 and Ari Polachek6, 1Tel Aviv Medical Center, Kfar Saba, Israel, 2Tel-Aviv Medical Center, Tel-Aviv, Israel, 3Tel-Aviv Medical Center, Petah-Tikva, Israel, 4Tel-Aviv Medical Center, EVEN-YEHUDA, Israel, 5Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 6Tel-Aviv Medical Center, Tel-Aviv, Israel, Petah-Tikva, Israel

    Background/Purpose:  Psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) are commonly diagnosed in young males in their reproductive years. However, only a few studies have investigated…
  • Abstract Number: 0580 • ACR Convergence 2024

    Cellular Immune Activation Signatures at Baseline Predict Response to TNF Inhibitors in Axial Spondyloarthritis

    Ayantika Talukdar1, Neke Ibeh2, Rohan Machhar2, Mansi Aparnathi3, Sareh Keshavarazi4, Archita Srinath5, Akihiro Nakamura6, Robert Inman7, Proton Rahman8, Igor Jurisica9 and Nigil Haroon10, 1Krembil Research Institute, UHN, Toronto, ON, Canada, 2UHN, Toronto, Canada, 3University Health Network, Toronto, Canada, 4UHN, Toronto, ON, Canada, 5University of Toronto, Toronto, ON, Canada, 6Queen's Univesity, Kingston, ON, Canada, 7University Health Network, Toronto, ON, Canada, 8Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada, 9Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, Toronto, ON, Canada, 10Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) substantially improve symptoms in Ankylosing Spondylitis (AS), although 40% patients are unresponsive. Identifying biomarkers predictive of TNFi treatment response…
  • Abstract Number: 1316 • ACR Convergence 2024

    Dual Therapy with a JAKi and bDMARD in Patients with Standard Treatment Resistant Rheumatic Disease: A Case Series

    Bella Garg1, John Antowan2 and daniel Furst3, 1Centinela Hospital Medical Center, Inglewood, CA, 2UCLA, Los Angeles, 3Pacific Arthritis Center, Inglewood

    Background/Purpose: Due to concerns about side effects, combined JAK inhibitors (JAKi) and biologic DMARDs (bDMARDs) have not been recommended for rheumatologic conditions. However, combining them…
  • Abstract Number: 1710 • ACR Convergence 2024

    Extl3 Involved in the Regulation of Endochondral Ossification in Axial SpA

    Stéphane Hilliquin1, OLIVIER FOGEL2, Mathilde Tissier3, Chahrazad Cherifi4, Karim Ibrahim5, Judith Melki6, Robert Olaso7, Brigitte Baroukh5, Philippe Dieudé8, Lars Rogge3, Elisabetta Bianchi3, Marcio Do Cruzeiro9, Frederique Cornelis10, Rik Lories10, Patricia Albanese4, Xavier Houard11, Claire Bardet5 and Corinne MICELI12, 1Département de Rhumatologie, Hôpital Cochin, Assistance publique des Hôpitaux de Paris, Université Paris-Cité, Paris, France, PARIS, France, 2AP-HP, Paris, France, 3Institut Pasteur, Université Paris Cité, Immunoregulation Unit, F-75015 Paris, France, PARIS, France, 4Laboratoire Gly-CREET, Université Paris-Est Créteil Val de Marne (UPEC) Faculté des sciences et technologies, Créteil, France, 5Université Paris Cité, Institut des maladies musculo-squelettiques, Laboratory Orofacial Pathologies, Imaging and Biotherapies URP2496 and FHU-DDS-Net, Dental School, and Plateforme d’Imagerie du Vivant (PIV), Montrouge, France,, Montrouge, France, 6Université Paris-Saclay, Laboratory Diseases and Hormones of the Nervous Systems, Inserm U1195, Le Kremlin Bicêtre, France, Le Kremlin Bicêtre, France, 7Centre National de Recherche en Génomique Humaine, Institut de Biologie François Jacob, Evry, Evry, France, 8Departement of Rheumatology, AP-HP, Bichat Hospital, Paris, France, 9Plateformes PDA et MouseT'IC, Institut Cochin, Université Paris Cité, Paris, France, PARIS, France, 10Laboratory of Tissue Homeostasis and Disease, Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, Leuven, Belgium, 11Centre de Recherche Saint-Antoine, UMR_S938 INSERM /Sorbonne Université, Paris, France, Paris, France, 12Université de Paris Cité, APHP, Paris, France

    Background/Purpose: Spondyloarthritis (SpA) is an inflammatory rheumatic disease characterized, in its axial form, by lesions affecting the spine and/or sacroiliac joints (SIJ). Severe forms of…
  • Abstract Number: 2352 • ACR Convergence 2024

    Bimekizumab Treatment Was Efficacious to 2 Years Regardless of Duration of axSpA Symptoms: Results from Two Phase 3 Studies

    Sofia Ramiro1, Fabian Proft2, Raj Sengupta3, Astrid van Tubergen4, Anna Molto5, Lianne S Gensler6, Mitsumasa Kishimoto7, Vanessa Taieb8, Diana Voiniciuc9, Ute Massow10 and Victoria Navarro Compán11, 1Leiden University Medical Center, Bunde, Netherlands, 2Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 3Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 4Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 5Groupe Hospitalier Cochin, AP-HP, Paris, France, 6Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 7Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, 8UCB Pharma, Colombes, France, 9UCB Pharma, Slough, United Kingdom, 10UCB Pharma, Monheim am Rhein, Germany, 11La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain

    Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, showed efficacy to Week (Wk) 52 in patients (pts) with…
  • Abstract Number: 0540 • ACR Convergence 2024

    Nonsteroidal Anti-Inflammatory Drug Use and Incident Hypertension Among Patients with Axial Spondyloarthritis

    Jose Meade Aguilar1, Jean Liew2, Rachael Stovall3, Sofia Ramiro4 and Lianne S Gensler5, 1Boston Medical Center, Boston, MA, 2Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 3University of Washington, Seattle, 4Leiden University Medical Center, Bunde, Netherlands, 5Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA

    Background/Purpose: Patients with axial spondyloarthritis (axSpA) have a heightened risk of cardiovascular morbidity and mortality. Nonsteroidal anti-inflammatory drugs (NSAIDs) are first line treatment for axSpA,…
  • Abstract Number: 0590 • ACR Convergence 2024

    Efficacy of Secukinumab Across the Axial Spondyloarthritis Spectrum Among Patients Grouped by Age (≥40 Years vs < 40): A PostHoc Analysis of 6 Phase 3 Trials

    Sofia Ramiro1, Corine Gaillez2, Uta Kiltz3, Lianne S Gensler4, Chaitali Pisal5, Juergen Braun6 and Alexis Ogdie7, 1Leiden University Medical Center, Bunde, Netherlands, 2Novartis Pharma AG, Basel, Switzerland, 3Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, 4Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 5Novartis Healthcare Private Limited, Hyderabad, India, 6Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, 7Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Secukinumab is an IL-17 inhibitor approved to treat axial spondyloarthritis (axSpA), including radiographic (r)-axSpA and non-radiographic (nr)-axSpA. Recent ASAS-EULAR recommendations highlight the importance of…
  • Abstract Number: 1435 • ACR Convergence 2024

    Prevalence, Progression, and Associated Factors of Enthesopathy at Hip and Pelvic Regions in Patients with Axial Spondyloarthritis: Computed Tomography-based Assessment

    Seong-Hyeok Bak, Kyung-Ann Lee, Eunsun Oh, Hyun-Sook Kim and Seunghyun Kim, Soonchunhyang University Seoul Hospital, seoul, Republic of Korea

    Background/Purpose: Axial spondyloarthritis (axSpA) is a group of related inflammatory diseases characterized by enthesitis, synovitis, and osteitis. The assessment of axial enthesitis in the pelvis…
  • Abstract Number: 1712 • ACR Convergence 2024

    Transcriptome Analysis Characterizes the Role of Monocytes in Ankylosing Spondylitis with TNF-blocker Treatment

    Yulong Tang1, Jiangnan Xie2, Dachun Zhuo1, Qi ZHU3, Jiucun Wang1 and Jing Liu2, 1Fudan University, Shanghai, China (People's Republic), 2Fudan University, Shanghai, Shanghai, China (People's Republic), 3Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China (People's Republic)

    Background/Purpose: Ankylosing spondylitis (AS) is an autoimmune and auto-inflammatory disease characterized by chronic inflammation of the spine, sacroiliac joint, and occasionally peripheral joints. TNF-α inhibitor…
  • Abstract Number: 2363 • ACR Convergence 2024

    “How Quickly Will I Feel Better with This New Drug?” – Rapidity of Treatment Response in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Analysis from Two Phase 3 Studies

    Atul Deodhar1, Elena Nikiphorou2, Abhijeet Danve3, Stephen Hall4, Vanessa Taieb5, Diana Voiniciuc6, Marina Magrey7 and Xenofon Baraliakos8, 1Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 2King's College London, London, United Kingdom, 3Section of Rheumatology, Department of Medicine, Yale School of Medicine, New Haven, CT, 4Cabrini Medical Centre, Monash University, and Emeritus Research, Melbourne, Victoria, Australia, 5UCB Pharma, Colombes, France, 6UCB Pharma, Slough, United Kingdom, 7Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH, 8Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. Two phase 3 studies were conducted where treatment…
  • Abstract Number: 0546 • ACR Convergence 2024

    Hiding in Plain Sight: The Impact of Implementing an Automated Inflammatory Back Pain Screening Tool on the Identification of Axial Spondyloarthritis in a Community Rheumatology Practice

    Nehad Soloman1, Jawad Bilal2 and John Tesser3, 1Arizona Arthritis & Rheumatology Associates, P.C., Glendale, AZ, 2Arizona Arthritis & Rheumatology Associates, PC, Tucson, AZ, 3Arizona Arthritis and Rheumatology Associates, P.C., Phoenix, AZ

    Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease affecting 1.4% of the US adult population.  The leading clinical symptom of axSpA is chronic inflammatory…
  • Abstract Number: 0603 • ACR Convergence 2024

    Superior Effectiveness and Comparable Drug Retention of Anti-TNF Therapy versus Anti-IL-17A in Ankylosing Spondylitis After First Anti-TNF Failure: A Propensity Score-Matched Analysis from the Czech ATTRA Registry

    Jakub Závada1, Jana Baranová2, Karel Pavelka1, Jiří Vencovský3, Pavel Horak4, Kateřina Kusalová2 and Ladislav Šenolt3, and collaborators of the ATTRA registry, 1Institute of Rheumatology and Charles University, Praha, Czech Republic, 2Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, 3Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 43rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic

    Background/Purpose: This study aims to compare the drug survival, effectiveness, and safety of anti-IL-17A and anti-TNF drugs in patients with Ankylosing Spondylitis (AS) following the…
  • Abstract Number: 1437 • ACR Convergence 2024

    Impact of Early Diagnosis in Patients with Axial Spondyloarthritis on Arterial Stiffness Progression

    Sze-Lok Lau1, Huan Meng2, Isaac Cheng1, Bryan PY Yan1, Alex PW Lee1, Ho So1 and Lai-shan Tam3, 1The Chinese University of Hong Kong, Hong Kong, Hong Kong, 2The Faculty of Medicine, CUHK, Hong Kong, China (People's Republic), 3The Chinese University of Hong Kong, New Territories, Hong Kong

    Background/Purpose: In patients with axial spondyloarthritis (AxSpA), we have reported that higher inflammatory burden as reflected by a longer disease duration, delay in diagnosis and…
  • Abstract Number: 1759 • ACR Convergence 2024

    Predictors of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis Receiving IL-17A Inhibitor or TNF Inhibitor Therapy over 2 Years: A Post Hoc Analysis of a Phase IIIb Study

    Denis Poddubnyy1, Juergen Braun2, Pedro M Machado3, Victoria Navarro Compán4, Lianne S Gensler5, Kay Geert Hermann6, Erhard Quebe-Fehling7, Christelle C Pieterse8, Aimee Readie9, Corine Gaillez7 and Xenofon Baraliakos10, 1Charite-Universitatsmedizin Berlin, Berlin, Germany, 2Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, 3Department of Neuromuscular Diseases and Centre for Rheumatology, University College London, London, United Kingdom, 4La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, 5Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 6Charite Medical School, Berlin, Germany, 7Novartis Pharma AG, Basel, Switzerland, 8Syneos Health, Amsterdam, Netherlands, 9Novartis Pharmaceuticals Corporation, East Hanover, NJ, 10Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany

    Background/Purpose: Previous studies have identified predictors of radiographic spinal progression in patients with axial spondyloarthritis (axSpA). In this post hoc analysis of the SURPASS study…
  • Abstract Number: 2367 • ACR Convergence 2024

    Updated Long-Term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Pooled Results from Phase 2b/3 Studies

    Philip Mease1, Denis Poddubnyy2, Rajan Bajracharya3, Barbara Ink3, Alexander Marten4, Ute Massow4, Vishvesh Shende3, Myriam Manente5, Luke Peterson6, Katy White3, Peter Nash7 and Lianne S Gensler8, 1Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 2Charite-Universitatsmedizin Berlin, Berlin, Germany, 3UCB Pharma, Slough, United Kingdom, 4UCB Pharma, Monheim am Rhein, Germany, 5UCB Pharma, Braine-l'Alleud, Belgium, 6UCB Pharma, Morrisville, NC, 7School of Medicine, Griffith University, Sunshine Coast, Queensland, Australia, 8Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA

    Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL‑17A. BKZ was generally well tolerated by patients (pts)…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 62
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology